00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...
00:52 , Jan 18, 2019 |  BC Week In Review  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
22:52 , Jan 15, 2019 |  BC Week In Review  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
23:49 , Jan 14, 2019 |  BC Extra  |  Company News

AZ's Bohen departing after cancer-focused tenure

AstraZeneca plc (LSE:AZN; NYSE:AZN) said Sean Bohen is leaving as CMO and EVP of global medicines development after a tenure marked by mixed results for the pharma's checkpoint inhibitor. Shortly after Bohen joined the pharma...
20:50 , Jan 14, 2019 |  BC Extra  |  Company News

Ascletis to develop Alphamab’s PD-L1 antibody for HBV in China

Suzhou Alphamab Co. Ltd. (Suzhou, China) granted Ascletis Pharma Inc. (HKEX:1672) exclusive rights to develop and commercialize subcutaneous anti-PD-L1 antibody KN035 for HBV and other viral diseases in greater China. Ascletis believes KN035 is a...
22:04 , Jan 8, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Lung cancer Mouse studies suggest inhibiting tumor-associated macrophages (TAMs) with liposomal clodronate could help treat lung cancer. In a mouse model of Lewis lung carcinoma, a liposomal preparation of the bisphosphonate clodronate, which induces...
20:30 , Jan 4, 2019 |  BC Extra  |  Company News

Immunocore taps MedImmune's Jallal as CEO

TCR company Immunocore Ltd. (Abingdon, U.K.) hired Bahija Jallal as CEO. She was EVP of AstraZeneca plc (LSE:AZN; NYSE:AZN) and president of its MedImmune LLC subsidiary. Jallal, who joined MedImmune in 2006, oversaw the development...
13:47 , Jan 3, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting FGL1 alone or in combination with PD-L1 inhibition could help treat colorectal cancer. In tumor samples from patients with colorectal cancer, levels of...
01:28 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

AbbVie's Rova-T suffers another setback in SCLC

AbbVie Inc. (NYSE:ABBV) said on Dec. 5 that it will stop enrollment in the Phase III TAHOE trial of Rova-T rovalpituzumab tesirine as second-line treatment of advanced or metastatic small cell lung cancer after the...
01:10 , Dec 7, 2018 |  BC Week In Review  |  Clinical News

Tecentriq could be first front-line SCLC therapy approved in two decades

FDA accepted and granted Priority Review to an sBLA from Genentech Inc. for anti-PD-L1 mAb Tecentriq atezolizumab as first-line treatment of extensive-stage small cell lung cancer. Its PDUFA date is March 18, 2019. Genentech CMO...